Glyxambi (Empagliflozin/Linagliptin) Patent Expiration, LOE Window & CMS Spending

Glyxambi (Empagliflozin/Linagliptin) by Boehringer Ingelheim: FDA Orange Book core substance LOE 2029-02-01 (last listed 2037-12-08), 0 AB generics, $149.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBoehringer Ingelheim
FDA Application & PathwayN206073 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2029-02-01
Last Listed Patent or Exclusivity Date2037-12-08
Orange Book Patents (*PED Extensions)25 patents (12 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$149.3M
2024 Medicare Part D Spend$141.1M
2024 Medicaid Spend$8.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.